UTHR Q3 2022 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$516M+16.0% YoY

Gross Profit

$479M92.8% margin

Operating Income

$314M60.9% margin

Net Income

$239M46.4% margin

EPS (Diluted)

$4.91

QoQ Revenue Growth

+10.5%

Cash Flow

Operating Cash Flow

$259M

Free Cash Flow

$190M

Stock-Based Comp.

-$2M

Balance Sheet

Total Assets

$5.8B

Total Liabilities

$1.2B

Stockholders' Equity

$4.6B

Cash & Equivalents

$967M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$516M	$445M	+16.0%
Gross Profit	$479M	$417M	+14.8%
Operating Income	$314M	$229M	+37.4%
Net Income	$239M	$163M	+47.1%

Revenue Segments

Tyvaso

$258M50%

Remodulin

$114M22%

Orenitram

$88M17%

Unituxin

$46M9%

Adcirca

$11M2%

Geographic Segments

UNITED STATES

$500M97%

Non-US

$16M3%